Neuropsychiatric adverse effects of centrally acting antiobesity drugs.
about
Review: Miglitol has potential as a therapeutic drug against obesityNaltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to dateEndocannabinoid Signaling Regulates Sleep StabilityAssessment of cognitive safety in clinical drug developmentObesity: Current and potential pharmacotherapeutics and targets.New and emerging drug molecules against obesity.The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.Neuroendocrine circuits governing energy balance and stress regulation: functional overlap and therapeutic implicationsAM404 attenuates reinstatement of nicotine seeking induced by nicotine-associated cues and nicotine priming but does not affect nicotine- and food-taking.An evolving scientific basis for the prevention and treatment of pediatric obesitySibutramine-induced mania as the first manifestation of bipolar disorder.Role of the endogenous cannabinoid system in nicotine addiction: novel insights.The selective anandamide transport inhibitor VDM11 attenuates reinstatement of nicotine seeking behaviour, but does not affect nicotine intakeEngineering endomorphin drugs: state of the art.Pharmacotherapy for childhood obesity: present and future prospects.Neurogenetics and Epigenetics in Impulsive Behaviour: Impact on Reward CircuitryProtection from Radiation-Induced Pulmonary Fibrosis by Peripheral Targeting of Cannabinoid Receptor-1.CB(1) receptor allosteric modulators display both agonist and signaling pathway specificity.Phentermine, sibutramine and affective disorders.Ribose Accelerates Gut Motility and Suppresses Mouse Body Weight GainingEffects of the mu-opioid receptor antagonist GSK1521498 on hedonic and consummatory eating behaviour: a proof of mechanism study in binge-eating obese subjectsPharmacotherapy for obesity: novel agents and paradigms.Investigation of Mendelian forms of obesity holds out the prospect of personalized medicine.Limitations in anti-obesity drug development: the critical role of hunger-promoting neurons.Investigational drugs in Phase II clinical trials for the treatment of obesity: implications for future development of novel therapies.Latest approaches for the treatment of obesity.Novel investigational drugs for constipation-predominant irritable bowel syndrome: a review.Cannabinoid signaling in health and disease.Does modulation of the endocannabinoid system have potential therapeutic utility in cerebellar ataxia?Evaluation of the effect of acute sibutramine in female rats in the elevated T-maze and elevated plus-maze tests.18β-glycyrrhetinic acid attenuates anandamide-induced adiposity and high-fat diet induced obesity.Salicortin-derivatives from Salix pseudo-lasiogyne twigs inhibit adipogenesis in 3T3-L1 cells via modulation of C/EBPα and SREBP1c dependent pathway.Opposing neural effects of naltrexone on food reward and aversion: implications for the treatment of obesity.Exploring the first Rimonabant analog-opioid peptide hybrid compound, as bivalent ligand for CB1 and opioid receptors.Early phytocannabinoid chemistry to endocannabinoids and beyond.Functional reversal of (-)-Stepholidine analogues by replacement of benzazepine substructure using the ring-expansion strategy.The cannabinoid-1 receptor inverse agonist taranabant reduces abdominal pain and increases intestinal transit in mice.
P2860
Q26775478-6586617D-F561-4526-81E2-F55FE17DDB49Q27014110-31576744-2B1E-411E-A603-3CCFA346C0FCQ27316124-74B0A822-3F33-4468-990C-03689C7A77FDQ28084637-F0363958-569F-4926-935C-DC0F4025C49AQ30243992-51CBF9CF-A145-464D-A6A4-C12B9BE1AA74Q30353872-0DABC40C-2E35-41CD-9F73-40C270CCE678Q30596646-FAFAE94C-455A-4388-8F83-72F1761FF41BQ33717424-7104D785-2B55-41F5-A338-EB892315A3F8Q33759649-EE9E414D-E5CD-4A2A-80EA-E3B1DED943AEQ34028763-E996D309-6B25-484A-811F-5EA6592906B7Q34274278-24417054-88B5-4CA7-B648-410DC3F7DFF6Q35216481-9F1BF1BF-18F8-4E87-9E54-D7696B562FE1Q35593066-2CB73437-39D5-4DD2-8AC7-B945B8C5F246Q35660653-E0742C16-B243-4E70-BADB-9F9ABA0D907BQ36468087-A73400B5-755C-404D-A5BF-8794CD5FC85DQ36477153-0E36A5CC-495D-4AB4-A17E-B615FE1D2A9BQ36548944-B37C24EB-EDB9-4666-92A1-43EACD846FBAQ36573169-57380127-963F-43A0-B102-612D12AB1E9EQ36832356-CAE7E697-E5FF-4321-82C2-DDC112D145B8Q36911092-79BFA792-AB4D-467D-97A5-6A2F3EAFB87CQ37330686-01EE9898-4CC0-4933-A2AB-6E299B59619AQ37712227-FD512EB5-A480-4DED-90CA-24D7F57DD394Q37822862-A882F803-35BE-4405-B254-EA9FD65CC0B9Q38031743-3E14002A-BA0A-4757-A1A4-5B989463978EQ38226897-962A5C34-3ADF-4ECC-B122-B8A066D590A6Q38475978-ABE6FC1A-83C8-4CE0-AEB3-0837BC772E43Q38696256-FAA7AF4E-4743-4EEE-B5CC-1381484938D9Q39163671-EA72C6BF-034A-4415-A843-72C27E7AC393Q41761143-30FB7EFB-8802-45DC-BA72-73A5A370C2E4Q42618077-6C27C4C9-FC26-473C-B613-131574BADDA3Q42804678-BA8B5495-5D4C-497B-B991-D355B5F4CA8AQ42814169-B146E269-B1D4-4C29-8883-526C51DF1B11Q43578699-88302576-E0AC-4C7E-8A0E-AEE10746233CQ44342705-8C1A6A29-51F1-46C5-B96B-97775328700AQ48062717-7C4D0908-FDD1-40BC-AA41-9DC737EBA88CQ50848946-F76F3134-F4AE-415C-8E47-28CDD2968C01Q50975152-FE36CCE9-B20C-4F12-84FB-E06F7240B94F
P2860
Neuropsychiatric adverse effects of centrally acting antiobesity drugs.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Neuropsychiatric adverse effects of centrally acting antiobesity drugs.
@en
Neuropsychiatric adverse effects of centrally acting antiobesity drugs.
@nl
type
label
Neuropsychiatric adverse effects of centrally acting antiobesity drugs.
@en
Neuropsychiatric adverse effects of centrally acting antiobesity drugs.
@nl
prefLabel
Neuropsychiatric adverse effects of centrally acting antiobesity drugs.
@en
Neuropsychiatric adverse effects of centrally acting antiobesity drugs.
@nl
P2093
P2860
P1476
Neuropsychiatric adverse effects of centrally acting antiobesity drugs
@en
P2093
Antonella Napolitano
Barry V O'Neill
Pradeep J Nathan
P2860
P304
P356
10.1111/J.1755-5949.2010.00172.X
P577
2010-07-07T00:00:00Z